Skip to content
Study details
Enrolling now

A Study of LY4515100 in Healthy Participants

Eli Lilly and Company
NCT IDNCT07339722ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1

Target enrollment

40

Study length

about 6 months

Ages

18–65

Locations

1 site in TX

What this study is about

This trial is testing the safety and how well LY4515100 is tolerated when given to healthy people. Blood tests will be done to see how the body processes the drug and its effects on the body. The study will last up to 30 days and include six overnight stays.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take LY4515100 via MAD
  • 2.Take LY4515100 via SAD

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Endpoints

Primary: Number of participants with one or more serious adverse event(s) (SAEs) of LY4515100

Secondary: PK: Maximum Observed Drug Concentration (Cmax) of LY4515100, PK: Time of maximum observed drug concentration (tmax) of LY4515100, Pharmacokinetics (PK): Area Under the Concentration versus Time Curve (AUC) of LY4515100